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L1 retrotransposons comprise 17% of the human genome and are its only autonomous mobile elements. Although
L1-induced insertional mutagenesis causes Mendelian disease, their mutagenic load in cancer has been elusive. Using L1-
targeted resequencing of 16 colorectal tumor and matched normal DNAs, we found that certain cancers were excessively
mutagenized by human-specific L1s, while no verifiable insertions were present in normal tissues. We confirmed de novo L1
insertions in malignancy by both validating and sequencing 69/107 tumor-specific insertions and retrieving both 59 and 39
junctions for 35. In contrast to germline polymorphic L1s, all insertions were severely 59 truncated. Validated insertion
numbers varied from up to 17 in some tumors to none in three others, and correlated with the age of the patients.
Numerous genes with a role in tumorigenesis were targeted, including ODZ3, ROBO2, PTPRM, PCM1, and CDH11. Thus,
somatic retrotransposition may play an etiologic role in colorectal cancer.
[Supplemental material is available for this article.]
Over two-thirds of our genome may stem from ‘‘jumping genes’’
(de Koning et al. 2011). Three classes of retroelements are known to
be currently active and a source of human disease: long inter-
spersed elements (LINEs), the prototype of which is the RNA
polymerase II transcribed L1; short interspersed elements (SINEs),
consisting essentially of RNA polymerase III transcribed Alus; and
SVAs (SINE-R/VNTR/Alus) that are intermediate in size relative to
Alus and L1s, and are likely transcribed by RNA polymerase II. A
fourth class of retroelements in our genome, human endogenous
retroviruses (HERVs) is considered immobile. Full-length L1s are
not only responsible for mobilizing themselves, but also for mo-
bilizing the nonautonomous Alu (Dewannieux et al. 2003) and
SVA retrotransposons (Ostertag et al. 2003; Hancks et al. 2011; Raiz
et al. 2011), inactive L1s (Moran et al. 1996), small RNAs (Gilbert
et al. 2005), and classical mRNAs, thereby creating processed pseu-
dogenes (Esnault et al. 2000; Wei et al. 2001; Ohshima et al. 2003).
Although there are about half a million L1s in the human
genome, only the human-specific L1s (L1Hs) are currently active,
represented in each individual by about 800 germline copies
(Ewing and Kazazian 2010), including;200 full-length sequences
(Boissinot et al. 2000). According to conservative estimates there
are only about 100 active L1Hs in any human diploid genome that
are retrotranspositionally competent, of which six from the refer-
ence genome and 37 from six other genomes are known to be
highly active (‘‘hot’’) (Brouha et al. 2003; Beck et al. 2010). L1s
retrotranspose through a process called target-primed reverse
transcription (TPRT) (Luan et al. 1993; Cost et al. 2002) with the
help of the L1-encoded proteins open reading frame 1 protein
(ORF1p) and ORF2p. Endonuclease and reverse transcriptase ac-
tivities for L1 integration are provided by ORF2p (Mathias et al.
1991; Feng et al. 1996). The hallmarks of TPRT are the addition of
a new poly(A) tail to the integrated sequence and target-site du-
plication (TSD), usually 6–20 bp in length. A fraction of retro-
transposition events are also associated with 39 transduction, the
comobilization of 39 flanking DNA sequences (Holmes et al. 1994;
Moran et al. 1999; Goodier et al. 2000; Pickeral et al. 2000),
resulting from transcriptional read-through of the weak L1 poly(A)
signal and preferential use of a stronger downstream poly(A) sig-
nal. Most de novo L1 retrotransposition events are 59 truncated
(Gilbert et al. 2005), with one extreme truncation described where
the whole L1 sequence was missing and only the 39 transduced
sequence was present (Solyom et al. 2012).
Active mobile elements are not only a significant source of
intra- and interindividual variation, but can also act as insertional
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mutagens. There are 97 known disease-associated retrotransposon
insertions into protein-coding genes (Hancks and Kazazian 2012;
van der Klift et al. 2012), which is an underestimate, as conven-
tional mutation screening methods are not designed to amplify
large insertions. Of these nearly 100 cases, 25 are caused by L1s, 60
by Alus, eight by SVAs, and four by poly(A) sequence originating
from an unidentifiable source (Hancks and Kazazian 2012; van der
Klift et al. 2012). Of these insertions, 30 occur in cancer cases, in-
cluding four in colon cancer patients (Miki et al. 1992; Su et al.
2000; Kloor et al. 2004; van der Klift et al. 2012).While three of the
four colon cancer cases involve predicted germline or early somatic
insertions, a somatic L1 insertion occurred in the APC gene in
colon cancer (Miki et al. 1992).
In addition to acting as insertionalmutagens, retrotransposons
can disrupt gene function and genomic integrity in many other
ways. These include recombination-mediated gene rearrangements,
genetic instability, transcriptional interference, alternative splicing,
gene breaking, epigenetic effects, the generation of DNA double-
strand breaks, and the expression of small noncoding RNAs (for
review, see Goodier and Kazazian 2008; Beck et al. 2011). All of
these mechanisms are compatible with a tumorigenic potential of
these elements. Retrotransposon overdose is another potential
scenario in malignancy and could result in increased insertional
mutagenesis, toxicity, or other oncogenic effects. Indeed, the
overexpression of L1 ORF1p was observed in certain tumors
(Bratthauer and Fanning 1992; Asch et al. 1996; Su et al. 2007;
Harris et al. 2010), and RNAi-mediated silencing of L1s resulted in
reduced proliferation and differentiation of tumorigenic cell lines
(Oricchio et al. 2007). In addition, overexpression of Alu elements
may exert disease through RNA toxicity (Kaneko et al. 2011). Thus,
the cell likely has intrinsic defense mechanisms to prevent retro-
transposon overexpression, including methylation (Yoder et al.
1997; Bourc’his and Bestor 2004) and the expression of several host
proteins, such as APOBEC3 family members (Bogerd et al. 2006;
Chen et al. 2006; Muckenfuss et al. 2006; Stenglein and Harris
2006) or DNA repair enzymes (Gasior et al. 2006; Suzuki et al. 2009;
Coufal et al. 2011).
Here we applied two high-throughput L1-targeted resequenc-
ing methods to discover retrotransposon activity in colorectal
cancers. We identified numerous nonreference L1 insertions not
present in paired normal tissue and report a high retrotransposon
insertion rate in tumors.We characterized insertion size andTSDs in
cancer tissue, confirming that L1s primarily mobilize in cancer via
TPRT. The data suggest the importance of retrotransposition in the
biology of colorectal tumorigenesis.
Results
L1 display through high-throughput sequencing
We applied two next generation resequencing methods—hemi-
specific PCR coupled to Illumina sequencing (L1-seq) (Ewing and
Kazazian 2010) and retrotransposon capture sequencing (RC-seq)
(Baillie et al. 2011) to interrogate the retroelement load of co-
lorectal tumors. Approximately 800 nonreference L1Hs copies had
been located from individual blood or lymphoblastoid cell lines by
L1-seq—the same number as represented by the hg18 reference
genome assembly, indicating its capacity to recover essentially all
germline L1Hs elements (Ewing and Kazazian 2010). Here, we
applied this method to recover somatic insertions frommalignant
tissues. RC-seq has previously been used to identify somatic mo-
saicism associated with L1, Alu, and SVA mobilization in the brain
(Baillie et al. 2011). Its use of sequence capture for retrotransposon
enrichment contrasts with the use of PCR by L1-seq; as a result,
RC-seq is expected to cover a broader range of insertions, but with
less depth per insertion than L1-seq. A highly multiplexed version
of RC-seq was applied to assess whether somatic L1Hs insertions
were identified by both approaches.
We sequenced DNA from 16 colorectal tumors and matched
normal colons using a pooled L1-seq-based approach. The 16
tumor/normal pairs (32 samples total) were separated into four
libraries of eight samples each denoted ‘‘colo1/tumor,’’ ‘‘colo1/
normal,’’ ‘‘colo2/tumor,’’ and ‘‘colo2/normal.’’ We sequenced one
lane for each library on an Illumina HiSeq 2000 instrument with
the exception of colo1/normal, where two lanes of data were
generated. The total number of reads generated for each library can
be found in Supplemental Table S1.
Using computationalmethods outlined in Ewing andKazazian
(2010), we identified clusters of reads localized 39 of predicted in-
sertion sites.We required 100 reads spanning at least 100 bp (‘‘high
stringency’’) as a minimum for L1 detection, which yields a spec-
ificity of >90% based on recovery of reference L1 insertions and
nonreference sites discovered in previous studies (see Supplemen-
tal Figs. S1, S2 for an exploration of cutoff parameters). Using these
criteria, we identified 764 reference L1Hs insertion sites present in
NCBI36/hg18 and 400 nonreference insertion sites from the colo1
data. From the colo2 data we identified 816 reference and 433
nonreference insertions. Combining the data, we found 819 refer-
ence L1Hs elements and 635 nonreference elements, 336 of which
had not been previously cataloged. Many of these uncataloged ele-
ments are new somatic insertions in the tumor. In total, 38% of
reference and 35% of nonreference insertions were in gene annota-
tions based on UCSC Known Genes. The distribution of L1 inser-
tions detected by L1-seq in this study is shown in Figure 1.
Our primary interest in generating these data was in finding
insertions present either in a cancer pooled library or in a normal
Figure 1. Genomic distribution of L1 insertions. Outer rings show the
density of detected insertion sites for reference (gray) and nonreference
(black) L1s. The approximate locations of the 72 PCR-validated somatic
insertions are indicated by dots inside the circle. Note that 69 of the 72
insertions were successfully sequenced.
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pooled library and not present in the corresponding paired normal
or tumor library. Turning to these,with the same stringency cutoffs
as above, we found 35 putative insertions only in colo1/tumor,
four only in colo1/normal, 50 predictions only in colo2/tumor,
and eight only in colo2/normal. Decreasing the requirements for
predicted insertions to 10 reads spanning at least 100 bp (‘‘low
stringency’’), we found 69 potential insertions only in colo1/tu-
mor, 173 only in colo1/normal, 75 only in colo2/tumor, and 42
only in colo2/normal. The dramatic increase in predictions for
colo1/normal only with decreasing stringency is an effect of the
higher coverage in the colo1/normal versus colo1/tumor (Supple-
mental Table S1), as two lanes of sequence were generated for
colo1/normal.
Five of the L1-sequenced colorectal tissue pairs were bar-
coded, pooled, and analyzed by shallow, multiplexed RC-seq (10
libraries, ;75 million paired-end Illumina GAIIx reads). A total of
26,903 nonreference genomic insertions were detected by at least
one read (Supplemental Table S2). Of these, 358 were (1) found in
only one donor, (2) were not identified in RC-seq previously per-
formed on pooled blood (Baillie et al. 2011) or databases of retro-
transposon polymorphisms (Huang et al. 2010; Iskow et al. 2010;
Ewing and Kazazian 2011), and (3) could
be annotated with high confidence due to
detection by multiple unique amplicons.
Of this set, 96 were only found in tumor,
including eight L1, 83 Alu, and five SVA. A
total of 39 insertions were found only in
nontumor samples and 223 were found in
both tumor and nontumor. The tumor:
nontumor ratios for L1, Alu and SVA, were
;8:1, 2.5:1, and 2:1, respectively. AluY and
L1-Ta/pre-Ta were detected, but no HERVs
were detected.
PCR validation
We applied a step-wise PCR amplification
scheme to validate insertion sites from
L1-seq data and to determine both 59 and
39 junctions of L1Hs elements identified
by L1-seq. Primary validations focused on
confirming the presence of de novo L1
inserts by amplifying their 39 junction
and determining which of the eight pa-
tients carried the insertion within a DNA
pool (PCR scheme and primer design
performedaccording toEwingandKazazian
2010) (Fig. 2A,B). An L1 insertion was
considered to be validated as tumor spe-
cific if the filled site (L1-containing) PCR
product was present in the tumor, but not
in the paired normal tissue, and in the
case of heterozygous autosomal insertions,
the empty site PCR product (WT allele)
was amplified from both members of
the tissue pair. Using a single PCR condi-
tion to amplify the 39 junctions, we PCR-
validated 26/40 and 37/51 insertions
from the colo1 and colo2 high-stringency
data sets, respectively. We also set out to
PCR amplify 16 colo1 insertions repre-
sented by less than 100 Illumina reads
and were able to validate nine. Thus, we PCR-validated before se-
quencing the 39 ends of 72 of 107 putative insertions (Supple-
mental Table S3; Supplemental Text S1).
Interestingly, among 12 high-stringency putative insertions
from normal colon of the combined colo1 and colo2 data sets,
none could be validated. Possible explanations for false positives in
the L1-seq data include PCR artifacts arising during library prepa-
ration, suboptimal PCR conditions used for validation, or L1 in-
sertion into repetitive sequences, refractory to successful primer
design.
Our stepwise PCR amplification scheme continued by re-
trieving the 59 junctions of tumor-specific L1 insertion events.
Several empty-site PCRs had already yielded a higher molecular
weight band exclusively in the tumor, which in each case was
verified to be a highly truncated L1 element (Fig. 2B). In the re-
maining cases, long-range PCR and a PCR specifically designed to
amplify the 59 end of a full-length L1 were used to retrieve the 59
junction.
Altogether, out of 72 cases where the insertions were PCR-
validated to be tumor specific, we successfully sequenced either the
39 or the 59 junction in 69 cases (Supplemental Table S3; Supple-
Figure 2. PCR validation scheme of L1-seq results. (A) The three-step PCR validation scheme and
location of primers used. Triangles symbolize TSD. (B) PCR validation of the 39 junction (ins. 7). This
insertion is in tumor 1 of the eight DNA samples that had been pooled for Illumina sequence analysis
(left), while the right panel shows it is present exclusively in the tumor, but not in the normal colon. The
higher molecular weight band visible above the ins. 7 empty site PCR product in the tumor is a highly
truncated L1. (T) Tumor; (N) normal colon; (FS) filled site PCR product; (ES) empty site PCR product.
Solyom et al.
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mental Text S1). For 35 insertions, we sequenced both junctions,
enabling us to characterize TSDs and L1 insertion size in cancer
tissue (Table 1). Surprisingly, all of the tumor-specific insertions
were highly truncated, the mean L1 insertion size being 585 bp,
excluding the poly(A) tail (Table 1).
Using a PCR designed to amplify full-length L1 insertions, we
failed to amplify the 59 end of any of the remaining tumor-specific
insertions where 59 junctions could not be identified with the
previous PCR approaches. On the other hand, three of 10 germline
polymorphic insertions had an intact 59 end, in agreement with
30% of reference L1Hs elements being full length (Pavlicek et al.
2002). This difference between full-length L1 insertions in tumors
(;0%) versus full-length insertions among polymorphic germline
L1Hs (;30%) is statistically significant (P = 0.016, Fisher’s exact
test) and is a clear departure from what is observed from the ref-
erence genome and from heritable nonreference insertions (Ewing
and Kazazian 2010).
L1-seq results on five tumors were corroborated by RC-seq.
Eleven high-confidence L1Hs hits were found in these cancers by
L1-seq, out of which four were also detected by RC-seq at either the
59 or 39 junction (ins. 5, 9, 14, and 32) (Supplemental Tables S2, S3;
Supplemental Text S1). Among eight high-confidence L1 inser-
tions within genes detected by RC-seq, but missed by L1-seq, one
was validated as present in tumor 10, targeting the DGKI gene
(Supplemental Table S2) (Fig. 3). Of the remaining putative tumor-
specific insertions that could be PCR-amplified, six of eight L1s, 30
of 57 Alus, and six of 11 SVAs were present in both tumor and
paired normal tissue.No other confirmed tumor-specific insertions
from the L1-seq data were found by RC-seq.
In order to determinewhether L1s are frequentlymobilized in
other nonmalignant somatic tissues, we performed L1-seq on ge-
nomic DNA extracted from cerebrum, liver, and testis samples
from two other individuals (cadaver samples) who had died from
arteriosclerotic cardiovascular disease. None of the Illumina high-
stringency sequence peaks suggestive of somatic L1 insertion could
be PCR-validated, implying that the high rate of somatic L1 in-
sertions observed in colon cancer was specific to the malignant
tissue. Thus, we have no evidence from our data of somatic inser-
tions in normal colon, liver, testis, or cerebrum.
Characterization of tumor-specific insertions
Intriguingly, the number of validated L1 insertions varied widely
from tumor to tumor with up to 17 insertions in some and none in
three others (Fig. 3). Most retrotransposition events showed hall-
marks of TPRT, namely TSD (27/35), L1 endonuclease cleavage site,
the presence of L1 poly(A) tail, frequent 59 inversion (10/35), and
in one case, a 39 transduction (Table 1). However, we note that a
substantial fraction of these somatic insertions (8/35) lacked a TSD
and six of these lacked a discernible endonuclease cleavage site,
suggesting that they were endonuclease-independent insertions
(Morrish et al. 2002). Two insertions (‘‘3’’ and ‘‘21’’) contained 39
sequence from other chromosomes, but lacked a poly(A) tail in
between the two sequences that would indicate a 39 transduction.
Thus, they are likely cancer-associated recombination events
(Supplemental Table S3; Supplemental Text S1).
Numerous genes were targets for insertional mutagenesis in
colon tumors by L1s that are represented in the COSMIC database
(Catalogue of Somatic Mutations in Cancer, http://www.sanger.
ac.uk/genetics/CGP/cosmic/). Examples include PTPRM (protein
tyrosine phosphatase, receptor type, M), ODZ3 (odd Oz/ten-m
homolog 3), ROBO2 (roundabout, axon guidance receptor, ho-
molog 2), PCM1 (pericentriolar material 1), and CDH11 (cadherin-
11). PCM1 and CDH11 are also represented in Sanger’s Cancer
Gene Census (http://www.sanger.ac.uk/genetics/CGP/Census/).
Interestingly, according to COSMIC, in the large intestine these
genes were mutated with the following high frequencies: PTPRM
(50%), ODZ3 (100%), ROBO2 (15%), PCM1 (12%), CDH11 (52%).
All of our hits were intronic and were PCR validated as well as se-
quenced. Additional interesting genes with a potential role in
malignancy were also targeted, for instance, RUNX1T1 (runt-
related transcription factor 1), a member of the myeloid trans-
location genes. Interestingly, somatic RUNX1T1 point mutations
were not only found in colorectal cancers (Wood et al. 2007), but
the product of the related RUNX3 gene regulates L1 expression
(Yang et al. 2003).
Cellular timing of L1 retrotransposition
In an effort to determine at what point in tumorigenesis the L1
insertions occurred, we developed three lines of evidence: analysis
of SNPs in sequence flanking the L1 insertion and the empty site,
the number of empty site X chromosome alleles in males who had
an L1 insertion into the X, and the presence/absence of the L1
insertion in a second section of a particular tumor in which an L1
insertion occurred.
First, we found three insertions (C2, C4, and insertion 31)
with flanking heterozygous SNPs. For C2 (ODZ3 gene) there was
one SNP, for C4 there were four SNPs, and for insertion 31 there
was one flanking SNP (Supplemental Fig. S3A). The presence of
both alleles of the particular SNP in the empty site chromosomes is
informative in case of no aneuploidy at the respective alleles. If
the insertion occurred at the initiation of the tumor (the one-cell
stage), the filled site would contain one allele and the empty site
would contain the other allele only. If both alleles are present in
the empty-site chromosomes, then the insertion likely occurred
after the one-cell stage of the tumor. The data showed that all six
SNPs near three different insertions in the empty-site chromo-
somes were heterozygous, suggesting that the insertions occurred
after the initiation of tumorigenesis. We carried out array com-
parative genomic hybridization (aCGH) and found no copy-
number gain or loss in the chromosomal arm of these SNPs (data
not shown), although small chromosomal aberrations at the re-
spective alleles cannot be ruled out.
Second, we found insertions (D9, D12, and E3) into the X
chromosome in twomales. If the insertion occurred at the one-cell
stage and the male did not have X-chromosome aneuploidy, the
tumor should lack an empty site. However, in all cases, we found
an empty-site band by PCR, indicating again that the insertions
occurred after the one-cell stage of tumorigenesis (Supplemental
Fig. S3B contains data on D9 and D12). Again, aCGH showed that
both males had a single X chromosome.
Third, we obtained a second portion of tissue from a number
of tumors and determinedwhether the insertions found in the first
tumor tissues could be confirmed in the second tumor sample. In
three of seven instances (insertionsC2, D7, and E3) wewere able to
confirm the insertion in a second tumor sample, suggesting a rel-
atively early event in tumorigenesis. Four other insertions (‘‘31,’’
‘‘A10,’’ ‘‘C4,’’ ‘‘D12’’) were present in the first tumor section, but
not in the second (Supplemental Fig. S3C). In tumor 2853, two
insertions were studied: E3 was present in both tumor portions,
while D12 was not, suggesting that these two insertions occurred
at different times and in different cells of the tumor (data not
shown). Furthermore, heterozygosity for L1 flanking SNPs in in-
L1 insertions in colon cancer
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sertions 31 and C4 in the original tumor sample, as well as the
absence of the insertion from the second tumor portion both
suggest late insertion events. Thus, from the combination of these
data on a small sample size we conclude that most, if not all, of the
studied L1 insertions occurred after the initiation of the tumor.
However, a minority of the insertions may have occurred at an
early stage of tumorigenesis. Furthermore, we cannot exclude the
possibility of tumor blood vessels or infiltrating lymphocytes as
contributing alternative explanations for some of the results.
Effects of L1 retrotransposition on measures of cellular
instability
To address the increased rate of somatic L1 retrotransposition in
tumors, we assessed the genomic landscape of the tissue samples
by aCGH, microsatellite instability (MSI), and L1 promoter meth-
ylation status. A previous report demonstrated a correlation of
genome-wide DNAmethylation status of tumors with increased de
novo L1 insertions (Iskow et al. 2010). We assessed the methyla-
tion status of the L1 promoter at four different CpG sites. Although
L1 promoter hypomethylation was found in tumor samples
compared with paired normal tissue, no correlation was observed
between L1 methylation status and the number of L1 insertions
(Fig. 4A).
For aCGH, we analyzed normal and tumor tissue from six
patient samples, two that possessed the greatest number of de novo
tumor insertions (12 and 1775), two with no tumor insertions (8
and 7647), and the two males mentioned above with both empty
and filled insertion sites in X chromosomes (17 and 2853). Tumor
samples 8, 12, 17, and 1775 contained complex chromosomal
changes, including entire and partial chromosomal gains and
losses. Tumor samples 2853 and 7647 presented no detectable
aberrations relative to normal tissue. Interestingly, three of the
samples (12, 17, and 1775) with complex chromosomal rear-
rangements had a high number of validated insertions. Likewise,
patient 7647 with no validated L1 in-
sertions had no detectable chromosomal
changes. The outliers from the trend of a
direct relationship between chromosomal
aberrations and L1 insertions were pa-
tients 8 and 2853. Interestingly, these
latter patients are potentially genetically
predisposed to colon cancer due to fa-
milial cancer aggregation or a very young
age of diagnosis.
In addition to analysis of gross ge-
nomic abnormalities, we assessed the
status of the mismatch DNA repair path-
way by assessing microsatellite expansions
in the genome. Seven of the 16 patients
were MSI positive. Although two samples
with the highest number of somatic L1
insertions were MSI positive, MSI status
did not correlate with the number of de
novo L1 insertions for each tumor (Fig. 4B).
Interestingly, a statistically signifi-
cant correlation was observed between
the number of insertions and the age
of the investigated patients (P = 0.01425,
R2 = 0.3128, where age is the time of
surgical sample removal). Eight or more
validated insertions were observed only
in the tumors of patients 78 yr old or older. An outlier in the cor-
relation was a 72-yr-old with no validated insertions. However, he
was the only proband with rectal cancer, but no colon tumor di-
agnosis.When this patient was excluded from the analysis, as well as
cases with a presumed genetic predisposition to colon cancer (fa-
milial polyposis case and a 17-yr-old male), an evenmore significant
correlation was observed between the age of sporadic colon
cancer patients and L1 activity (P = 0.001548, R2 = 0.578) (Fig. 4C).
Discussion
Our L1-seq method has revealed a high rate of L1Hs retro-
transposition in certain colorectal cancer genomes. The neigh-
boring matched normal colon sample in these 16 cases, as well as
cerebrum, liver, and testis from two other individuals yielded no L1
insertions that could be validated, indicating few or no retro-
transposition events in these normal tissues.
Iskow et al. (2010) used 454 pyrosequencing to search for de
novo L1 insertions in five glioblastomas, fivemedulloblastomas, as
well as leukemia and breast cancer cell lines, but they found no
insertions in these cases. However, they identified nine somatic L1
insertions in six of 20 lung tumors. Since TSDs were not reported,
the question of whether L1 integration in lung cancer occurs
through TPRT remained open.
Herewe report that evolutionarily youngL1Hs retrotransposons
can mobilize themselves through the classical TPRT mechanism
in colon cancer genomes at a high frequency. The true retro-
transposition rate is likely to be even higher, as our method does
not detect insertions mobilized by L1 elements in trans, such as
Alus, SVAs, most inactive L1s, and processed pseudogenes. In ad-
dition, there are likely other L1 insertions in our data set that have
not been subjected to validation. Longer tumor-specific 39 trans-
ductions will be missed as well, as it is difficult to differentiate
between the progenitor and the transduced sequence by their 39
flank with L1-seq.
Figure 3. Distribution of somatic L1 insertions in tumors. Insertions in black were detected by L1-seq,
while the insertion in tumor 10 in white was detected by RC-seq only.
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In order to determine why the rate of somatic cell retro-
transpositionwas high in some tumors compared with the normal
tissue, we assessed how the following factors correlate with retro-
transposition rate: age of colorectal cancer patients, chromosomal
aberrations, L1 methylation status, and mismatch DNA repair as
reflected by MSI. A clear correlation of retrotransposition activity
was observed with the age of colon cancer patients in sporadic
cases. Furthermore, we also analyzed genetic instability by aCGH
in six samples and found a modest association between the num-
ber of chromosomal aberrations and the age of the sporadic colon
cancer patients. Altogether, it is possible that the hypomethylated
microenvironment of the tumors, together with genetic instability
as reflected by MSI and gross chromosomal changes, have a cu-
mulative effect in older patients. Our results are in agreement with
the correlation of retrotransposition activity with genome insta-
bility during yeast chronological aging (Maxwell et al. 2011).
In this study, we found that genes with a known driver
function in cancer are mutagenized by L1Hs elements. The accu-
mulation of retrotransposon sequences is predicted to cause fur-
ther genetic instability through recombination. Thus, an elevated
insertion rate is expected to contribute to tumor evolution. As
exemplified by a somatic L1 insertion into theAPC gene (Miki et al.
1992), it is clear that in some fraction of colorectal cancers retro-
transposon insertions can be etiologically significant. Yet, it re-
mains unclear in what fraction of cases retrotransposons initiate
malignant transformation and in how many instances they con-
tribute solely to a more aggressive phe-
notype. SNP, X chromosome, and second-
ary sampling data from tumor samples
suggest that L1 insertions likely occurred
at various times after the initiation of the
tumor. Although we found no evidence
for L1 insertion into colon cancer tumor-
suppressor genes or oncogenes that would
be indicative of driver mutation-induced
tumor clonality, analysis of a larger num-
ber of tumors or a deeper sequencing of
retrotransposon insertions could uncover
such events. We propose that it is possible
to estimate insertion timing and tumor
heterogeneity more precisely by evaluat-
ing pure tumor samples. Our findings are
in agreement with a very recent report
on retrotransposon insertions in epithelial
cancers (Lee et al. 2012). Intriguingly, an
intronic L1 integration eventwas found in
that study as well in the ROBO2 gene in
a colon tumor. Additionally, they detected
intronic L1 insertions inCDH12, while we
characterized an insertion into theCDH11
gene. Thus, the role of cell-adhesion genes
in retrotransposon insertion-mediated
colorectal tumorigenesis may deserve fur-
ther investigation.
An unexpected finding of our PCR-
based validation is the severely truncated
nature of all validated L1 insertions in
colon cancer. It was not possible to assess
whether this is a general characteristic of
the malignant phenotype, of all somatic
tissues, or of the gastrointestinal tract in
particular, as no de novo L1 insertions
could be uncovered from normal colon, liver, testis, and brain. In
a transgenic mouse model, 30 of 33 somatic L1 insertions were 59
truncated (Babushok et al. 2006), raising the possibility of a gradual
decrease in L1 size from germline to somatic to malignant in-
sertions. In cultured HeLa cells, 94/100 insertions were 59 trun-
cated (Gilbert et al. 2005). This might indicate that some cancer
tissues or cultured cells could allow full-length insertions to accumu-
late. The overexpression of an exogenous L1 element, coupled with
the bias toward recovering larger inserts in that assay, and the un-
known effects of cell culture conditions on retrotransposition com-
plicate transferring conclusions on the L1 59 truncation rate to cancer
tissue. Likewise, it is not understood why the majority of germline L1
insertions are 59 truncated as opposed to Alu and SVA insertions that
are mostly full length, yet also mobilized by L1s (Hancks et al. 2011).
The truncated structure of L1 elements in colorectal cancer
may be useful in understanding the mechanism of 59 truncation
both in normal and tumor cells. We propose two possible expla-
nations: (1) If TPRT timing is coupled to the cell cycle, the elevated
cell division rate ofmalignant cellsmay not leave sufficient time to
complete integration of long mobile elements; (2) a DNA repair
pathway might monitor and remove de novo mobile element
insertions in healthy tissues. Once this presumed surveillance
pathway is down-regulated in cancer, retrotransposon insertions
are not removed efficiently and are allowed to accumulate. At the
same time, another or the same DNA repair pathway might spe-
cialize in truncating fresh integrants or prohibiting them from
Figure 4. Analysis of factors influencing L1 activity. (A) L1 CpG promoter methylation status per-
formed by quantitative bisulfite PCR analysis. (N) Normal tissue; (T) tumor tissue; (*) MSI. Replicates of
four were done for each data point. (Error bars) Standard deviations. (B) MSI analysis. 6% TBE gel
depicting the status of five microsatellite repeats (BAT25, BAT26, D2S123, D17S250, D17346 in
descending order) in normal and tumor tissue from two different patients. Tumor tissue ‘‘6’’ contained
additional bands and gel shifts compared with the normal tissue, indicating MSI. Samples from ‘‘8’’
demonstrated no differences suggestive of MSI. (C ) Correlation of L1 activity with age of the patient at
time of surgery. See text for details.
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completing retrotransposition. If this process is up-regulated, the
truncation rate increases. The efficiency of such a pathway might
correlate with insertion size or be sequence specific, thus prefer-
entially targeting L1 elements over Alus and SVAs. Interestingly,
nonhomologous end joining (NHEJ) is an important DNA repair
pathway candidate with a reported conflicting dual role in regu-
lating retrotransposon insertions, offering an explanation for
parallel L1 up-regulation and truncation (Suzuki et al. 2009). We
propose that by comparing the genomeor transcriptome of tumors
with a high rate of retrotransposition to their paired normal tis-
sues, we may discern clues to cellular factors causing L1 mobili-
zation and 59 truncation.
To conclude, the cancerous colon of many patients is the
second reported organbeside the brain (Baillie et al. 2011) inwhich
a high rate of retrotransposition occurs. Lung, prostate, and ovar-
ian tumors are also reported to allow a lower level of L1 mobili-
zation (Iskow et al. 2010; Lee et al. 2012), but many other cancer
types appear to be nonpermissive for a detectable rate of retro-
transposition. All L1 insertions in the colorectal tumors of this
study were highly truncated, potentially indicating the footprint
of a defective or hyperactive DNA repair pathway in cancer. The
cause and effect of retrotransposon mobilization in cancers war-
rants further investigation.
Methods
Human DNA samples
DNA was extracted from human patient tissue samples acquired
from the University of Minnesota Tissue Procurement Facility
from BioNet (IRB#0805E32181). See Supplemental Table S4 for
patient data. Briefly, 2 mg of tissue was digested overnight at 55°C
on a rotating platform in 710 mL of digest buffer (1 M Tris at pH
8.0, 1 mM EDTA, 13 SSC, 1% SDS, 1 Mm NaCl, 10 mg/mL Pro-
teinase K). Following digest, DNA was purified using phenol-
chloroform-isoamyl alcohol (Life Sciences) isolation protocol.
Human frozen tissue from two Caucasian cadavers with
arteriosclerotic cardiovascular disease were obtained from the
NICHD Brain and Tissue Bank for Developmental Disorders at the
University of Maryland, Baltimore. DNA isolation was done uti-
lizing the AllPrep DNA/RNA Mini Kit (Qiagen).
Library construction, sequencing, and analysis
L1-seq
The library for L1Hs elements was made according to Ewing and
Kazazian (2010), while the library for L1, Alu, and SVA elements
(RC-seq) was constructed according to Baillie et al. (2011). L1Hs
elements were TOPO-TA cloned (Invitrogen) and Sanger-se-
quenced for quality control of the library preparation, and were
subsequently sequenced on an Illumina HiSeq 2000 at the Johns
Hopkins University Genetic Resources Core Facility High Through-
put Sequencing Center.
Pooled L1-seq library sequence data was analyzed as described
previously (Ewing and Kazazian 2010), and compared against in-
sertion sites of known reference and nonreference transposable
elements (Beck et al. 2010; Ewing and Kazazian 2010, 2011; Huang
et al. 2010; Iskow et al. 2010;Witherspoon et al. 2010;Hormozdiari
et al. 2011; Stewart et al. 2011). Gene annotations were obtained
from UCSC Known Genes (Hsu et al. 2006).
RC-seq
The library for retrotransposon capture and sequencing was cre-
ated utilizing DNA from five pairs of colorectal and normal tissue
(samples 1; 4; 6; 8; 10) by the samemethod as published previously
(Baillie et al. 2011). One significant change was made to the
technique, in that liquid phase hybridization was performed as
opposed to solid surface, chip-based hybridization. The libraries
were then sequenced on an Illumina Genome Analyzer II and
aligned to the genome by a computational pipeline that utilized
SOAP2 to align reads to the genome and used much the same
method as published (Ballie et al. 2011; R Shukla, KR Upton,
M Mun˜oz-Lopez, DJ Gerhardt, JK Baillie, ME Fisher, PM Brennan,
A Collino, S Ghisletti, S Sinha, et al., in prep.).
PCR validation of the Illumina results
A three-step PCR validation protocol was used to validate the next-
generation sequencing reads and to retrieve 39 and 59 junctions. As
the first step, L1 39 ends together with flanking genomic regions
were amplified using the same AC dinucleotide–specific primer of
L1Hs as used for Illumina sequencing (L1Hs primer: GGGAGAT
ATACCTAATGCTAGATGACAC) and a primer selected from the 39
flanking region based on the reference genome sequence (FS
primer). PCR reactions were carried out in 12.5 mL of 23 GoTaq
Green master mix (Promega) in a total volume of 25 mL, with 0.8
mL of FS primer, 1.5 mL of L1Hs primer, and 25 ng of DNA to am-
plify the filled site. The empty site was amplified with the same
conditions, except that 1.5 mL of FS primer, 1.5 mL of ES primer,
and 12.5 ng of DNAwere used. Primers were 20 pmol/mL and their
location is depicted in Figure 2A. Reactions were incubated for 2
min at 95°C, followed by 30 cycles of 30 sec at 95°C, 30 sec at 57°C,
and 1.5min at 72°C, followed by a final extension of 5min at 72°C
on a PTC-200 Peltier Thermal Cycler. Long-range PCR to recover
longer L1 insertionswas performedwith the Expand Long Template
PCR System (Roche) according to the manufacturer’s instructions
in buffer 1, with 1mL of 20mMFS and ES primers each, and 25 ng of
tumor DNA. 59 junctions were PCR amplified using the same
conditions as for the 39 junction, except that a primer hybridizing
to the L1 59UTR was used (L1nt112out: GATGAACCCGGTACCT
CAGA) together with the respective ES primer, and primer exten-
sion time was only 45 sec. FS and ES primer sequences are included
in the Supplemental Material (Supplemental Table S1). PCR
products were cut out of the gel, extracted with the QIAquick Gel
Extraction Kit (Qiagen), and sequenced. See Supplemental Text S1
for Sanger sequence data on insertions.
Microsatellite instability assays
To assess the MSI status, we utilized five markers recommended
by the National Cancer Institute (Bethesda markers): BAT25 and
BAT26 to assess mononucleotide repeats (A)n and D2S123,
D5S346, and D17S250 to assess dinucleotide repeats (CA)n. MSI
status was determined using previously established protocols
(Ashktorab et al. 2003; Muller et al. 2004). Primers were developed
by the NCI for screening patients in the clinic.
L1 methylation status
Themethylation level of L1 promoters was performed according to
Wilhelm et al. (2010). Briefly, each sample was amplified three
times and each amplification was pyrosequenced once. The aver-
age of the three was utilized to determine the value of CpG
methylation for each of the four positions analyzed for an L1.
aCGH
DNA frompatients 8, 12, 17, 1775, 2853, and 7647were restriction
digested and labeled with fluorochrome Cyanine-5 using random
Solyom et al.
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primers and exo-Klenow fragment DNA polymerase. DNA from
a sex-matched control was labeled concurrently with Cyanine-3.
The sample and control DNA were combined and array-based
comparative genomic hybridization (aCGH) and single nucleotide
polymorphism analysis (SNP) was performed with a 180K Cancer
CGH+SNP microarray constructed by Agilent Technologies, Inc.
that contains ;115,000 distinct biological oligonucleotides and
55,000 SNP sites, spaced at an average interval of 25 KB (for 20,000
cancer-associated CGH probes: one probe/0.5–1 KB). The ratio of
sample to control DNA for each oligo was calculated using Feature
Extraction software 10.10 (Agilent Technologies). The abnormal
threshold was applied using Cytogenomics 2.060 (Agilent Tech-
nologies). A combination of several statistical algorithms was ap-
plied. A minimum of three oligos that have a minimum absolute
ratio value of 0.1 (based on a log(2) ratio) is required for reporting
of a copy-number loss or gain. Analysis was performed using Hu-
man Genome Build 19 (Feb 2009) as the reference.
Data access
The sequence and phenotypic data from this study have been
deposited in dbGaP (http://www.ncbi.nlm.nih.gov/dbgap) under
accessionnumber phs000536.v1.p1. The dbGaP accessionnumber
assigned to this study is phs000536.v1.p1.
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